{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:11:53Z","timestamp":1791594713071,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s11910-016-0668-z","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T08:31:24Z","timestamp":1463041884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Muscle-Specific Receptor Tyrosine Kinase (MuSK) Myasthenia Gravis"],"prefix":"10.1007","volume":"16","author":[{"given":"Rebecca L.","family":"Hurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton L.","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"668_CR1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1988.00520260073024","volume":"45","author":"HB Marstellar","year":"1988","unstructured":"Marstellar HB. The first American case of myasthenia gravis. Arch Neurol. 1988;45:185\u20137.","journal-title":"Arch Neurol"},{"key":"668_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0733-8619(18)30094-X","volume":"12","author":"RM Pascuzzi","year":"1994","unstructured":"Pascuzzi RM. The history of myasthenia gravis. Neurol Clin. 1994;12:231\u201342.","journal-title":"Neurol Clin"},{"key":"668_CR3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","volume":"180","author":"J Patrick","year":"1973","unstructured":"Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973;180:871\u20132.","journal-title":"Science"},{"key":"668_CR4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8:475\u201390.","journal-title":"Lancet Neurol"},{"key":"668_CR5","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978\u201380.","journal-title":"Neurology"},{"issue":"3","key":"668_CR6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Sigrun H, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patient with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"668_CR7","first-page":"e77","volume":"2","author":"J Guptill","year":"2015","unstructured":"Guptill J et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurology: Neuroimmunol Neuroinflamm. 2015;2(2):e77. This paper explores and suggests a more definitive pathophysiology and immune mechanism for MuSK MG which may have an impact on future management.","journal-title":"Neurology: Neuroimmunol Neuroinflamm"},{"key":"668_CR8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/joa.12034","volume":"224","author":"I Koneczny","year":"2014","unstructured":"Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. 2014;224:29\u201335.","journal-title":"J Anat"},{"key":"668_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","volume":"284","author":"AI Tsonis","year":"2015","unstructured":"Tsonis AI, Zisimopoulou P, Lazaridis K, et al. MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2014a multinational study. J Neuroimm. 2015;284:10\u20137.","journal-title":"J Neuroimm"},{"key":"668_CR10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","volume":"52","author":"JS Yi","year":"2014","unstructured":"Yi JS et al. Characterization of CD4 and CD8 T cell response in MuSK myasthenia gravis. J Autoimmun. 2014;52:130\u20138. This papers explores and suggests a more definitive pathophysiology and immune mechanism for MuSK MG which may have an impact on future management.","journal-title":"J Autoimmun"},{"key":"668_CR11","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304\u201311.","journal-title":"Brain"},{"key":"668_CR12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","volume":"68","author":"F Deymeer","year":"2007","unstructured":"Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical Comparison of anti-MuSK vs. anti-AChR-positive and seronegative myasthenia gravis. Neurology. 2007;68:609\u201311.","journal-title":"Neurology"},{"key":"668_CR13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","volume":"12","author":"A Evoli","year":"2013","unstructured":"Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12:931\u20135. This paper reviews clinical, diagnostic and management of MuSK MG based on current evidence.","journal-title":"Autoimmun Rev"},{"issue":"1-2","key":"668_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2005.08.016","volume":"170","author":"O Benveniste","year":"2005","unstructured":"Benveniste O et al. MuSk antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J Neuroimmunol. 2005;170(1-2):41\u20138.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"668_CR15","first-page":"1413","volume":"20","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Guptill J. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum. 2014;20(5):1413\u201325.","journal-title":"Continuum"},{"key":"668_CR16","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","volume":"116","author":"DE Stickler","year":"2005","unstructured":"Stickler DE, Massey JM, Sanders DB. MuSK-antibody positive myasthenia gravis: clinical and electrodiagnosic patterns. Clin Neurophysiol. 2005;116:2065\u20138.","journal-title":"Clin Neurophysiol"},{"key":"668_CR17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","volume":"2","author":"A Vincent","year":"2003","unstructured":"Vincent A et al. Seronegative generalized myasthenia gravis: clinical features, antibodies and their targets. Lancet. 2003;2:99\u2013106.","journal-title":"Lancet"},{"issue":"9","key":"668_CR18","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","volume":"65","author":"Y Hatanaka","year":"2005","unstructured":"Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology. 2005;65(9):1508\u20139.","journal-title":"Neurology"},{"key":"668_CR19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","volume":"33","author":"B Hain","year":"2006","unstructured":"Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33:575\u201380.","journal-title":"Muscle Nerve"},{"issue":"11","key":"668_CR20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","volume":"86","author":"A Evoli","year":"2016","unstructured":"Evoli A, Alboini PE, Damato V, Iorio R. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies. Neurology. 2016;86(11):1070\u20131.","journal-title":"Neurology"},{"issue":"11","key":"668_CR21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/WNL.0000000000002475","volume":"86","author":"L Hobson-Webb","year":"2016","unstructured":"Hobson-Webb L. Comment: is 3,4-diaminopyridine a new option in treating MuSK MG? Neurology. 2016;86(11):1071.","journal-title":"Neurology"},{"key":"668_CR22","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","volume":"64","author":"L Lauriola","year":"2005","unstructured":"Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and negative myasthenia gravis. Neurology. 2005;64:536\u20138.","journal-title":"Neurology"},{"key":"668_CR23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"J Guptill","year":"2011","unstructured":"Guptill J, Sanders DB, Evoli A. Anti-MuSk antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Musc and Nerv. 2011;44:36\u201340.","journal-title":"Musc and Nerv"},{"key":"668_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"2","author":"V Juel","year":"2007","unstructured":"Juel V, Massey J. Myasthenia gravis. Orphanet J Rare Disease. 2007;2:44.","journal-title":"Orphanet J Rare Disease"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0668-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-016-0668-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-016-0668-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T15:19:39Z","timestamp":1567869579000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-016-0668-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s11910-016-0668-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]},"article-number":"61"}}